Please use this identifier to cite or link to this item:
|Author:||Abdelrahman , Fatma|
Daramola, Oluwasegun I.
Oduselu, Tolulope J.
Khan, Fazal Mehmood
Torrents Serra, Eduard
|Keywords:||Resistència als medicaments|
|Abstract:||Due to the global emergence of antibiotic resistance, there has been an increase in research surrounding endolysins as an alternative therapeutic. Endolysins are phage-encoded enzymes, utilized by mature phage virions to hydrolyze the cell wall from within. There is significant evidence that proves the ability of endolysins to degrade the peptidoglycan externally without the assistance of phage. Thus, their incorporation in therapeutic strategies has opened new options for therapeutic application against bacterial infections in the human and veterinary sectors, as well as within the agricultural and biotechnology sectors. While endolysins show promising results within the laboratory, it is important to document their resistance, safety, and immunogenicity for in-vivo application. This review aims to provide new insights into the synergy between endolysins and antibiotics, as well as the formulation of endolysins. Thus, it provides crucial information for clinical trials involving endolysins.|
|Note:||Reproducció del document publicat a: https://doi.org/10.3390/antibiotics10020124|
|It is part of:||Antibiotics, 2021, vol. 10, num. 2, p. 124|
|Appears in Collections:||Articles publicats en revistes (Genètica, Microbiologia i Estadística)|
This item is licensed under a Creative Commons License